Netupitant/palonosetron
Combination of | |
---|---|
Netupitant | NK1 receptor antagonist |
Palonosetron | 5-HT3 receptor antagonist |
Names | |
Trade names | Akynzeo |
Clinical data | |
Main uses | Chemotherapy-induced nausea and vomiting[1] |
Side effects | Headache, constipation, tiredness[2] |
Pregnancy category | |
Routes of use | By mouth, intravenous |
External links | |
AHFS/Drugs.com | Monograph |
MedlinePlus | a614053 |
Legal | |
License data | |
Legal status |
Netupitant/palonosetron, sold under the brand name Akynzeo, is a combination medication for prevention of acute and delayed chemotherapy-induced nausea and vomiting.[1] It is taken by mouth.[1] It is used with dexamethasone.[1]
Common side effects include headache, constipation, and tiredness.[2] The dose does not need to be adjusted in those with mild to moderate liver or kidney problems.[1] Use is not recommended in pregnancy.[7] Netupitant is an NK1 receptor blocker and palonosetron is a 5-HT3 receptor blocker.[2]
The combination was approved for medical use in the United States in 2014 and Europe in 2015.[1][2] In the United Kingdom it costs the NHS about £70 a dose as of 2021.[7] In the United States this amount costs about 680 USD.[8]
Medical use
Dosage
The typical dose is one capsule a hour before chemotherapy.[2] This contains 300 mg of netupitant and 0.5 mg of palonosetron.[1]
There is an intravenous version that contains fosnetupitant and palonosetron.[9][6]
Contraindications
Netupitant/palonosetron may be contraindicated during pregnancy.[10][3][4]
Side effects
The most common side effects include headache, weakness, fatigue, upset stomach, constipation, and skin redness.[6] The overall profile of adverse effects is comparable to that of palonosetron (see Palonosetron#Adverse effects); no common adverse effects can be attributed to netupitant.[10]
Interactions
Pharmacology
History
Netupitant/palonosetron was approved for use in the United States in October 2014.[11] It was approved for use in the European Union in May 2015.[2] The intravenous version was approved in the United States in April 2018.[12][9]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "Netupitant/Palonosetron Monograph for Professionals". Drugs.com. Archived from the original on 28 January 2021. Retrieved 12 November 2021.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 "Akynzeo EPAR". European Medicines Agency (EMA). 19 March 2020. Archived from the original on 19 March 2020. Retrieved 19 March 2020.
- ↑ 3.0 3.1 3.2 "Netupitant / palonosetron (Akynzeo) Use During Pregnancy". Drugs.com. 22 October 2018. Archived from the original on 19 December 2019. Retrieved 19 March 2020.
- ↑ 4.0 4.1 "Fosnetupitant / palonosetron (Akynzeo for Injection) Use During Pregnancy". Drugs.com. 22 October 2018. Archived from the original on 19 March 2020. Retrieved 19 March 2020.
- ↑ "Akynzeo 300 mg/0.5 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). 11 February 2020. Archived from the original on 19 March 2020. Retrieved 19 March 2020.
- ↑ 6.0 6.1 6.2 "Akynzeo- netupitant and palonosetron capsule Akynzeo- fosnetupitant and palonosetron injection". DailyMed. 28 May 2020. Archived from the original on 18 October 2020. Retrieved 18 July 2020.
- ↑ 7.0 7.1 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 456. ISBN 978-0857114105.
- ↑ "Akynzeo Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 19 April 2021. Retrieved 12 November 2021.
- ↑ 9.0 9.1 "Drug Trials Snapshots: Akynzeo". U.S. Food and Drug Administration (FDA). 11 May 2018. Archived from the original on 24 January 2020. Retrieved 19 March 2020.
- ↑ 10.0 10.1 Haberfeld H, ed. (2015). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Akynzeo 300 mg / 0,5 mg Hartkapseln.
{{cite book}}
: CS1 maint: unrecognized language (link) - ↑ "Drug Approval Package: Akynzeo (Netupitant and Palonosetron) Capsules NDA #205718". U.S. Food and Drug Administration (FDA). 7 November 2014. Archived from the original on 19 March 2020. Retrieved 19 March 2020.
- ↑ "Drug Approval Package: Akynzeo (fosnetupitant and palonosetron) Injection". U.S. Food and Drug Administration (FDA). 31 May 2018. Archived from the original on 19 March 2020. Retrieved 19 March 2020.
External links
- AusPAR: Fosnetupitant (as chloride hydrochloride)/palonosetron (as hydrochloride). Therapeutic Goods Administration (TGA) (Report). October 2020. Archived from the original on 4 November 2020. Retrieved 2 March 2021.
- "Netupitant mixture with palonosetron". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 19 December 2019. Retrieved 2 March 2021.
- "Fosnetupitant". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 19 March 2020. Retrieved 2 March 2021.
- "Fosnetupitant and Palonosetron (Professional Patient Advice)". Drugs.com. Archived from the original on 23 October 2020. Retrieved 2 March 2021.
Identifiers: |
---|
- Pages using duplicate arguments in template calls
- CS1 maint: unrecognized language
- Use dmy dates from December 2019
- Articles with invalid date parameter in template
- Drugs with non-standard legal status
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drug has EMA link
- Articles containing unverified chemical infoboxes
- Drugs that are a combination of chemicals
- Articles with hatnote templates targeting a nonexistent page
- Antiemetics
- Combination drugs